RECRUITING

Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

To collect and preserve glioblastoma tissue during standard of care tumor resection surgery and blood for future molecular and genetic testing. Tissue for research will be collected from three different regions within the same tumor to study how these regions differ in their structure, DNA, and RNA and also to compare the data obtained from this testing to imaging data found in the medical record. The goal of this study is to help us better understand what the glioblastoma tumor tissue looks like and how it functions. This understanding can lead to new therapies for the treatment of glioblastoma in the future.

Official Title

Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue (PRESERVE GBM)

Quick Facts

Study Start:2024-12-11
Study Completion:2029-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05756985

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Have the appearance of high-grade glioma on magnetic resonance (MR) imaging if allowed to consent and will undergo the procedure if the frozen is consistent with glioblastoma or gliosarcoma OR Patients with a history of histologically confirmed diagnosis of World Health Organization Grade glioblastoma or gliosarcoma that are undergoing repeat resection of a recurrent tumor as identified on preoperative MR imaging
  2. 2. Aged ≥ 18 years old
  3. 3. Contrast-enhancing tumor volume of at least 10 cc on the preoperative, volumetric MRI within 1 month prior to surgery
  4. 4. Provision of signed and dated informed consent form by participant or legally authorized representative (LAR), if applicable
  1. 1. Has a history or current evidence of any medical condition, therapy, or laboratory abnormality that might confound the results of the study or is not in the best interest of the participant, in the opinion of the treating investigator.

Contacts and Locations

Study Contact

Manmeet S Ahluwalia, M.D.
CONTACT
(786) 596-2000
manmeeta@baptisthealth.net
Michael McDermott, M.D.
CONTACT
(786) 596-2000
MWMCD@baptisthealth.net

Principal Investigator

Manmeet S Ahluwalia, M.D.
PRINCIPAL_INVESTIGATOR
Miami Cancer Institute at Baptist Health, Inc.

Study Locations (Sites)

Miami Cancer Institute at Baptist Health, Inc.
Miami, Florida, 33176
United States

Collaborators and Investigators

Sponsor: Baptist Health South Florida

  • Manmeet S Ahluwalia, M.D., PRINCIPAL_INVESTIGATOR, Miami Cancer Institute at Baptist Health, Inc.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-12-11
Study Completion Date2029-01

Study Record Updates

Study Start Date2024-12-11
Study Completion Date2029-01

Terms related to this study

Keywords Provided by Researchers

  • specimen banking

Additional Relevant MeSH Terms

  • Glioblastoma
  • Glioblastoma Multiforme
  • Gliosarcoma